Trade secrets can supercharge life science start-ups, if founders know how to use them
What is under-appreciated by many in the life sciences is just how many trade secrets they might have and just how much value they can secure by protecting them.
The 2024 SME Fund offered by the European Intellectual Property office (EUIPO) is now live. The scheme aims to help EU-based small and medium-sized enterprises (SMEs) with protecting their intellectual property (IP) rights.
Yesterday, in a highly anticipated ruling, the UPC Court of Appeal dismissed an appeal brought by Ocado in its litigation in the UPC against Autostore.
Did you know that lots of companies are looking to nature to make new textiles, construction materials, wound dressings, and other vital materials?
What is under-appreciated by many in the life sciences is just how many trade secrets they might have and just how much value they can secure by protecting them.
The AG Opinion in Mylan vs Gilead provides useful guidance as to when parties may obtain “appropriate compensation” from rights holders for wrongly granted interim measures.
The EPO’s Board of Appeal in T0116/18 has provided welcome clarity on the application of G2/21 relating to post-filed data for inventive step.
Counterfeit medicines are on the rise. According to the Pharmaceutical Security Institute, more than 6,500 pharmaceutical crimes were recorded across the globe in 2022.
Healthwashing is the term used to describe the act of making a product (most frequently a food or drink) appear healthier than it is by making certain claims.
The EU Commission published four proposals for amending the current regime for Supplementary Protection Certificates (SPCs) to enable a centralised examination of national and unitary SPCs. We summarise the proposals and some aspects of concern.
In June this year Europol Operation Pirates 1 took place seizing fake goods including counterfeit pharmaceuticals worth over €33m. Then between April and October another operation seized over 10.5 million medicinal products worth over €40m.
In a landmark ruling the local division of the Unified Patent Court (UPC) in Munich issued a preliminary injunction against NanoString Technologies based on European Patent 4 108 782 B1, successfully asserted by 10x Genomics and President and Fellows of Harvard College (licensee and patentee).
On 30 June 2023 the US District Court for the District of New Jersey ruled in favour of Orexo AB in its patent litigation against Sun in relation to ZUBSOLV® (buprenorphine and naloxone) sublingual tablets (CIII), with the Court ruling that Orexo’s patents are both valid and are infringed by Sun.
In April this year, the European Commission submitted its proposals for revisions to the EU’s pharmaceutical legislation governing the authorisation of medicinal products.
The House of Lords Sub-Committee on the Protocol on Ireland/Northern Ireland released its report on the Windsor Framework on 25 July 2023. In case you missed it, we summarise below how the Framework will affect the valuable intellectual property rights known as Supplementary Protection Certificates (SPCs) in the UK.
As 10 blockbuster drug patents expire, do pharma companies need to focus even more on patent term extensions & exclusivity strategy?